Deubiquitinating enzyme inhibitor alleviates cyclin A1‐mediated proteasome inhibitor tolerance in mixed‐lineage leukemia

Drug resistance is a significant obstacle to effective cancer treatment. Drug resistance develops from initially reversible drug‐tolerant cancer cells, which offer therapeutic opportunities to impede cancer relapse. The mechanisms of resistance to proteasome inhibitor (PI) therapy have been investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Maolin, Xu, Qiongyu, Kang, Ting, Li, Dan, Wang, Ruiheng, Chen, Zhihong, Xie, Shufeng, Wang, Wenbin, Liu, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177811/
https://www.ncbi.nlm.nih.gov/pubmed/33738896
http://dx.doi.org/10.1111/cas.14892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177811/
https://www.ncbi.nlm.nih.gov/pubmed/33738896
http://dx.doi.org/10.1111/cas.14892

Ejemplares similares